5 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 10 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Hypertrophic Cardiomyopathy: new trials by email Literature Review of Hypertrophic Cardiomyopathy trials Research Report on Hypertrophic Cardiomyopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring ATP-C135, ATP-C75 - Hypertrophic Cardiomyopathy | Phase 3 | Not yet recruiting | Yonsei University | 100 | 2025-03-01 | 2025-03-13 |
| Empagliflozin in Hypertrophic Cardiomyopathy Empagliflozin 10 MG, Placebo - Hypertrophic Cardiomyopathy, Heart Failure | Phase 3 | Active not recruiting | National Institute of Cardiology, Warsaw, Poland | 250 | 2022-06-01 | 2026-03-12 |
| Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy Sacubitril/Valsartan, Lifestyle - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | 168 | 2019-04-01 | 2022-05-09 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 314 | 2018-09-27 | 2026-02-20 |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
| Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy RF catheter ablation, Antiarrhythmic drugs - Atrial Fibrillation, Hypertrophic Cardiomyopathy | Phase 3 | Completed | National Institute of Cardiology, Warsaw, Poland | 90 | 2009-01-01 | 2013-02-05 |
| Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart Atorvastatin, Placebo - Hypertrophic Cardiomyopathy | Phase 3 | Completed | University of Calgary | 22 | 2007-04-01 | 2013-12-09 |
| Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Diltiazem, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 39 | 2006-01-01 | 2015-04-07 |
| Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure Perhexiline, Placebo - Hypertrophic Cardiomyopathy | Phase 3 | Withdrawn | Heart Metabolics Limited | 2017-07-14 | ||
| Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy Cardiac Resynchronisation Therapy - Hypertrophic Cardiomyopathy | Phase 3 | Unknown | University Hospital Birmingham | 32 | 2008-06-16 |
Cardiomyopathy, Hypertrophic (10) · Heart Failure (3) · Angina Pectoris (1) · Arrhythmias, Cardiac (1) · Atrial Fibrillation (1) · Cardiomyopathies (1) · Cardiomyopathy, Hypertrophic, Familial (1) · Death, Sudden, Cardiac (1) · Dyspnea (1) · Hypertrophy (1) · Hypertrophy, Left Ventricular (1)
Aortic Stenosis, Subvalvular (10) · Aortic Valve Disease (10) · Aortic Valve Stenosis (10) · Cardiovascular Diseases (10) · Heart Diseases (10) · Heart Valve Diseases (10) · Cardiomyopathies (9) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (2) · Pathological Conditions, Anatomical (2) · Arrhythmias, Cardiac (1) · Cardiomegaly (1) · Chest Pain (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Death (1)
Anti-Arrhythmia Agents (1) · Atorvastatin (1) · Cardiac Resynchronization Therapy (1) · Diltiazem (1) · MYK-461 (1) · Perhexiline (1) · eleclazine (1) · empagliflozin (1) · sacubitril and valsartan sodium hydrate drug combination (1)
National Institute of Cardiology, Warsaw, Poland (2) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Gilead Sciences (1) · Heart Metabolics Limited (1) · Newcastle-upon-Tyne Hospitals NHS Trust (1) · University Hospital Birmingham (1) · University of Calgary (1) · Yonsei University (1)
United Kingdom (4) · Poland (3) · United States (3) · France (2) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Portugal (1) · Spain (1)
Carolyn Y Ho, MD (1) · Djordje Jakovljevic, PhD (1) · Franciszek Walczak, MD, PhD (1) · Lidia Chojnowska, MD, PhD (1) · Lukasz Szumowski, MD, PhD (1) · Pawel Derejko, MD, PhD (1) · Robert S. Sheldon, MD, PhD (1)
PMID 27590665, PMID 28400935, PMID 38176782, PMID 39217450, PMID 42636950
K23HL078901 (1)